The Food and Drug Administration said it has appointed former biotech executive George Tidmarsh as the agency's top drug ...

Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated ...

Marty Makary, commissioner of the FDA, is naming George Tidmarsh director of the Center for Drug Evaluation and Research.

2025年7月3日，迪哲医药（股票代码：688192.SH）宣布，舒沃哲（ZEGFROVY，通用名：舒沃替尼片）的新药上市申请（New Drug ...

President Donald Trump's proposed budget cuts to the National Institutes of Health would eventually result in fewer drugs on ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

The FDA accepted Aldeyra's resubmitted NDA for reproxalap after previous rejections due to efficacy concerns, despite no ...

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...

An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Aldeyra Therapeutics (ALDX) stock in focus as the FDA accepts its resubmitted marketing application for lead drug reproxalap ...

A new report looks at hiring trends © 2025 American City Business Journals. All rights reserved. Use of and/or registration ...